Skip to main content

Table 5 Multivariate analysis for Relapse, NRM, LFS, OS, and GRFS

From: Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors

  Relapse NRM LFS OS GRFS
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
ATG vs PTCy 0.93 (0.63–1.37) 0.71 1.04 (0.65–1.66) 0.86 0.98 (0.74–1.29) 0.86 0.94 (0.7–1.27) 0.71 0.89 (0.7–1.13) 0.35
Age (per 10 years) 1.01 (0.92–1.11) 0.9 1.37 (1.2–1.56) < 10–5 1.13 (1.05–1.22) 0.001 1.21 (1.12–1.32) < 10–5 1.06 (1–1.14) 0.07
sec. AML vs de novo 1.14 (0.86–1.53) 0.36 1.39 (1.02–1.9) 0.04 1.24 (1.01–1.53) 0.04 1.29 (1.03–1.6) 0.02 1.25 (1.03–1.52) 0.02
Adverse cytogenetics vs other 1.77 (1.41–2.24) < 10–5 1.19 (0.88–1.61) 0.27 1.51 (1.26–1.81) < 10–5 1.42 (1.17–1.72) 0.0004 1.36 (1.15–1.61) 0.0003
Female donor-male recipient vs other 0.54 (0.36–0.8) 0.002 1.46 (1.04–2.05) 0.03 0.89 (0.69–1.15) 0.38 0.93 (0.71–1.22) 0.6 1.11 (0.89–1.38) 0.35
RIC vs MAC 1.06 (0.82–1.36) 0.66 0.84 (0.63–1.13) 0.25 0.97 (0.81–1.17) 0.75 0.91 (0.74–1.11) 0.33 0.98 (0.83–1.15) 0.77
KPS ≥ 90 1.16 (0.9–1.51) 0.26 0.85 (0.64–1.13) 0.27 1.02 (0.84–1.23) 0.86 0.98 (0.81–1.2) 0.87 0.96 (0.81–1.13) 0.60
Patient CMV positivity 0.99 (0.79–1.24) 0.92 1.31 (0.99–1.73) 0.06 1.11 (0.93–1.32) 0.24 1.12 (0.93–1.35) 0.22 1.11 (0.95–1.29) 0.21
Donor CMV positivity 1.17 (0.94–1.45) 0.16 1 (0.77–1.3) 0.98 1.09 (0.92–1.28) 0.33 1.09 (0.91–1.3) 0.34 1.11 (0.96–1.29) 0.16
Year of transplantation 1.04 (0.99–1.1) 0.12 1 (0.94–1.07) 0.99 1.02 (0.98–1.07) 0.26 1.02 (0.98–1.07) 0.37 1.03 (1–1.07) 0.07
PBSC vs BM 0.96 (0.68–1.36) 0.82 1.29 (0.8–2.09) 0.29 1.05 (0.8–1.39) 0.73 1.11 (0.82–1.49) 0.50 1.14 (0.88–1.47) 0.31
  1. Abbreviations: AML acute myeloid leukemia, ATG antithymocyte globulin, BM bone marrow, CI confidence interval, CMV cytomegalovirus, cGVHD chronic graft-versus-host disease, Ext extensive, GRFS graft-versus-host disease-free, relapse-free survival, HR hazard ratio, KPS Karnofsky Performance Status, LFS leukemia-free survival, MAC myeloablative conditioning regimen, NRM non-relapse mortality, OS overall survival, PBSC peripheral blood stem cell, PTCY post-transplantation cyclophosphamide, RIC reduced intensity conditioning regimen, sec.AML secondary acute myeloid leukemia